Find Clinical Drug Pipelines for Trauma (Emergency, Injury, Surgery)

Lead Product(s): Ronopterin

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injuries.

Lead Product(s): PRV-002

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

Prevacus, has completed GMP certification of API for their lead compound for treating concussion and is now preparing the final nano-formulation for nasal application to initiate its first human trials.

Lead Product(s): Nangibotide

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Roche Diagnostics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 21, 2020

Details:

Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

Lead Product(s): PB2452

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: SFJ Pharmaceuticals

Deal Size: $120.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 10, 2020

Details:

The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.

Lead Product(s): rhNELL-1

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

Lead Product(s): Dantrolene Sodium

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 06, 2020

Details:

Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.

Lead Product(s): Acetylcysteine Sodium

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: ATAI Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 06, 2020

Details:

The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.

Lead Product(s): Bromelain

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: MediWound

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 02, 2020

Details:

The agreement is part of MediWound's global commercialization strategy that will expand the medical and commercial potential of NexoBrid to treat skin burns.